Armistice Capital, LLC and Steven Boyd filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 1,325,537 shares of GeoVax Labs, Inc. common stock as of September 30, 2026.

Key Highlights

  • Beneficial ownership: Armistice Capital, LLC and Steven Boyd each reported beneficial ownership of 1,325,537 shares of GeoVax Labs common stock.
  • Percent of class: The 1,325,537 shares represent 9.99% of the class, according to the filing.
  • Shared voting and dispositive power: Both reporting persons reported 0 sole voting power and 0 sole dispositive power, with 1,325,537 shares held under shared voting and shared dispositive power.
  • Direct holder: The filing identifies Armistice Capital Master Fund Ltd. as the direct holder of the shares, with Armistice Capital, LLC serving as its investment manager.
  • Triggering event date: The date of the event requiring the filing was September 30, 2026.
  • Certifications: The reporting persons certified the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of GeoVax Labs.

Armistice Capital and Steven Boyd Disclose GeoVax Labs Position via Schedule 13G

According to the Schedule 13G filed on November 16, 2026, Armistice Capital, LLC, a Delaware-organized investment adviser, and Steven Boyd, a United States citizen and managing member of Armistice Capital, collectively disclosed a position in GeoVax Labs, Inc. (NASDAQ:GOVX) common stock, par value $0.001 per share. The filing was triggered by an event dated September 30, 2026, and covers CUSIP number 373678705.

The filing discloses that Armistice Capital Master Fund Ltd., described as "a Cayman Islands exempted company that is an investment advisory client of Armistice Capital," is the direct holder of the reported shares. Pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities held by the Master Fund. As managing member of Armistice Capital, Steven Boyd may also be deemed to beneficially own those securities. The filing notes that "the Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital."

The filing further states that the Master Fund "has the right to receive dividends from, or the proceeds from the sale of, the reported securities." Both Armistice Capital and Steven Boyd are listed as type IA/OO and HC/IN reporting persons, respectively. GeoVax Labs is headquartered at 1900 Lake Park Drive, Suite 380, Smyrna, Georgia 30080, according to the filing.

What Was Disclosed

Armistice Capital, LLC and Steven Boyd filed a Schedule 13G reporting shared beneficial ownership of 1,325,537 shares of GeoVax Labs common stock, equal to 9.99% of the class, as of September 30, 2026, with the Master Fund identified as the direct holder.